Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)

G9077
HCPCS Code

2023 HCPCS
Billable/Valid Code

G9077 is a valid 2023 HCPCS Code that could be used to indicate Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project) for reimbursement purposes.

G9077 belongs to Medical Care Type of Service and has been in effect since Jan 01, 2007.

Short description for G9077 HCPCS code:

Onc dx prostate t1no progres

HCPCS G9077

G9077 code information

HCPCS code:	G9077
Description:	ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T1-T2C AND GLEASON 2-7 AND PSA < OR EQUAL TO 20 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
Effective Date:	Jan 01, 2007
Added Date:	Jan 01, 2006
Termination Date:	HCPCS G9077 was terminated on Nov 30, -0001
Pricing indicator:	`00` - SERVICE NOT SEPARATELY PRICED BY PART B (E.G., SERVICES NOT COVERED, BUNDLED, USED BY PART A ONLY, ETC.) PHYSICIAN FEE SCHEDULE AND NON-PHYSICIAN PRACTITIONERS
Multi Pricing indicator:	`9` - NOT APPLICABLE AS HCPCS NOT PRICED SEPARATELY BY PART B (PRICING INDICATOR IS 00) OR VALUE IS NOT ESTABLISHED (PRICING INDICATOR IS ´99´)
Coverage code:	`C` - CARRIER JUDGMENT
BETOS code:	`P7B` - ONCOLOGY - OTHER
Action code:	`N` - NO MAINTENANCE FOR THIS CODE
Type of Service:	`1` - MEDICAL CARE
Anesthesia BUQ:	0